Laurence Reid - Net Worth and Insider Trading
Laurence Reid Net Worth
The estimated net worth of Laurence Reid is at least $1 Million dollars as of 2024-12-28. Laurence Reid is the SVP, Chief Business Officer of Alnylam Pharmaceuticals Inc and owns about 5,671 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $1 Million. Laurence Reid is also the President and Chief Executive of Decibel Therapeutics Inc and owns about 25,849 shares of Decibel Therapeutics Inc (DBTX) stock worth over $126,919. Details can be seen in Laurence Reid's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Laurence Reid has not made any transactions after 2021-09-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Laurence Reid
Laurence Reid Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Laurence Reid owns 2 companies in total, including Alnylam Pharmaceuticals Inc (ALNY) , and Decibel Therapeutics Inc (DBTX) .
Click here to see the complete history of Laurence Reid’s form 4 insider trades.
Insider Ownership Summary of Laurence Reid
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | 2014-11-18 | SVP & Chief Business Officer |
| DBTX | Decibel Therapeutics Inc | 2021-09-15 | director & See Remarks |
Laurence Reid Latest Holdings Summary
Laurence Reid currently owns a total of 2 stocks. Among these stocks, Laurence Reid owns 5,671 shares of Alnylam Pharmaceuticals Inc (ALNY) as of November 18, 2014, with a value of $1 Million and a weighting of 91.4%. Laurence Reid also owns 25,849 shares of Decibel Therapeutics Inc (DBTX) as of September 15, 2021, with a value of $126,919 and a weighting of 8.6%.
Latest Holdings of Laurence Reid
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ALNY | Alnylam Pharmaceuticals Inc | 2014-11-18 | 5,671 | 237.97 | 1,349,528 |
| DBTX | Decibel Therapeutics Inc | 2021-09-15 | 25,849 | 4.91 | 126,919 |
Holding Weightings of Laurence Reid
Laurence Reid Form 4 Trading Tracker
According to the SEC Form 4 filings, Laurence Reid has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 10,000 shares on November 18, 2014, which brought Laurence Reid around $906,700.
According to the SEC Form 4 filings, Laurence Reid has made a total of 1 transactions in Decibel Therapeutics Inc (DBTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Decibel Therapeutics Inc is the acquisition of 10,000 shares on September 15, 2021, which cost Laurence Reid around $76,400.
Insider Trading History of Laurence Reid
- 1
Laurence Reid Trading Performance
GuruFocus tracks the stock performance after each of Laurence Reid's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Laurence Reid is -23.35%. GuruFocus also compares Laurence Reid's trading performance to market benchmark return within the same time period. The performance of stocks bought by Laurence Reid within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Laurence Reid's insider trading performs compared to the benchmark.
Performance of Laurence Reid
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -3.56 | | | | | |
| Relative Return to S&P 500(%) | -4.95 | | | | | |
Laurence Reid Ownership Network
Laurence Reid Owned Company Details
What does Alnylam Pharmaceuticals Inc do?
Who are the key executives at Alnylam Pharmaceuticals Inc?
Laurence Reid is the SVP & Chief Business Officer of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include CMO & EVP Dev & Med Affairs Pushkal Garg , EVP & Chief Commercial Officer Tolga Tanguler , and Chief Financial Officer Jeffrey V. Poulton .
Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary
Over the past 18 months, Laurence Reid made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 57,750 shares made by Yvonne Greenstreet , a net sale of 13,738 shares made by Pushkal Garg , and a net sale of 7,321 shares made by Jeffrey V. Poulton .
In summary, during the past 3 months, insiders sold 14,804 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 14,804 shares. During the past 18 months, 263,932 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 263,932 shares.
Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Alnylam Pharmaceuticals Inc Insider Transactions
Laurence Reid Mailing Address
Above is the net worth, insider trading, and ownership report for Laurence Reid. You might contact Laurence Reid via mailing address: 300 Third Street, Cambridge Ma 02142.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
